Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Presentations of BAY 43-9006 at the 2004 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Time	Presentation Title	Abstract #	Speaker	Type
Saturday, 6/5/04	Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).	4501	Mark J. Ratain, MD	Integrated Education Sessions
Sunday, 6/6/04	A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study.	6611 (Poster #: L11)	Michael Crump, MD	General Poster Sessions
Sunday, 6/6/04	BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience.	7506	Tanya Ahmad, MRCP	Oral Presentation Sessions
Sunday, 6/6/04	Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma.	7507	Keith T. Flaherty, MD	Oral Presentation Sessions
Monday, 6/7/04	A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer.	3059 (Poster #: M9)	Lillian L. Siu, MD	General Poster Sessions
Monday, 6/7/04	Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors.	3049 (Poster #: L10)	Heike Richly, MD	General Poster Sessions
Monday, 6/7/04	Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors.	3056 (Poster #: M6)	Petra Kupsch, MD	General Poster Sessions
Tuesday, 6/8/04	Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.	2035 (Poster #: 25)	Maria Luisa Veronese, MD	Poster Discussion Sessions

Forward Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including its Form 20-F). Bayer assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, regulatory processes and commercialization efforts of BAY43-9006. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made Onyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2004 under the heading "Additional Business Risks" for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release except as required by law.

# # #

Leverkusen, June 7, 2004

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ute Krippendorf (+49-214-30-33021)
Ilia Kürten (+49-214-30-35426)
Judith Nestmann (+49-214-30-66836)